{"id":"cgb-400","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The drug aims to modulate a key biological process that contributes to the development or worsening of the targeted condition. The specific details of the mechanism are proprietary and have not been fully revealed.","oneSentence":"CGB-400 is designed to target and inhibit a specific pathway involved in disease progression, though the exact mechanism is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:50:23.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04886739","phase":"PHASE2","title":"CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea","status":"COMPLETED","sponsor":"CAGE Bio Inc.","startDate":"2021-05-07","conditions":"Rosacea","enrollment":78},{"nctId":"NCT05202366","phase":"","title":"An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection","status":"UNKNOWN","sponsor":"CAGE Bio Inc.","startDate":"2022-02-08","conditions":"Fungal Infection, Onychomycosis, Tinea Unguium","enrollment":15},{"nctId":"NCT04508205","phase":"PHASE1","title":"CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes","status":"COMPLETED","sponsor":"CAGE Bio Inc.","startDate":"2018-10-26","conditions":"Rosacea","enrollment":27},{"nctId":"NCT04508660","phase":"PHASE1","title":"CGB-400 for the Reduction of Facial Redness","status":"COMPLETED","sponsor":"CAGE Bio Inc.","startDate":"2018-10-26","conditions":"Rosacea","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CGB-400","genericName":"CGB-400","companyName":"CAGE Bio Inc.","companyId":"cage-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}